Fantom Encore
Coronary Artery Disease
CommercialActive
Key Facts
About REVA Medical
REVA Medical is a pioneer in bioresorbable polymer technology, having developed 19 polymer families over two decades. Its proprietary Tyrocore polymer platform underpins its commercial and pipeline products, including the CE-marked Fantom Encore coronary scaffold and the MOTIV BTK scaffold, which has FDA Breakthrough Designation. The company's strategy targets the large cardiovascular device market by offering temporary scaffolds that resorb, aiming to improve long-term patient outcomes compared to permanent metal implants. REVA operates as a commercial-stage entity in select European markets while advancing clinical programs for US market entry.
View full company profileTherapeutic Areas
Other Coronary Artery Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| MUTI™ Drug‑Eluting Stent | Meril | Commercial |
| Coronary Artery Bypass Grafts | Vascudyne | Pre-clinical |
| Premier DES | Relisys Medical Devices | Commercial |
| Release R DES | Relisys Medical Devices | Commercial |
| Pristine DES | Relisys Medical Devices | Commercial |
| BioMatrix family (Flex/Alpha) | Biosensors International | Commercial |
| Coronary Artery Disease Program | Elixir Medical | Pre-clinical |
| Essential pro Stent | iVascularU | Post-Market |
| FGF-1 | Zhittya Genesis Medicine | Phase 2 |
| OMT-28 | OMEICOS Therapeutics | Phase 2 |
| Next-Gen Drug-Eluting Stents | Translumina | Development |
| Geographic Market Expansion | Translumina | Commercial |